Contact
Please use this form to send email to PR contact of this press release:
Dr. Dayan Goodenowe Announces FDA Clinical Development Program for a Novel Alzheimer’s Therapeutic
TO:
Christine Haas
Christine Haas Media
+1 512-751-1592